Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma.
Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma.
复制标题
自身抗体作为食管鳞状细胞癌早期检测的潜在生物标志物。
DOI：
10.1038/ajg.2013.384
复制
发表时间：
2014-01
影响因子：
9.8
通讯作者：
Xu, Li-Yan
中科院分区：
文献类型：
--
作者：
Xu, Yi-Wei;Peng, Yu-Hui;Chen, Bo;Wu, Zhi-Yong;Wu, Jian-Yi;Shen, Jin-Hui;Zheng, Chun-Peng;Wang, Shao-Hong;Guo, Hai-Peng;Li, En-Min;Xu, Li-Yan
食管鳞癌(ESCC)是世界范围内最常见的癌症死亡原因之一，需要有效的诊断。我们评估了自身抗体组合的诊断潜力，这可能有助于早期诊断。我们分析了一组测试队列和一组验证队列中ESCC患者和正常对照组的数据。用酶联免疫吸附试验检测6种肿瘤相关抗原(P53、NY-ESO-1、基质金属蛋白酶-7(MMP7)、热休克蛋白70(HSP70)、过氧化还蛋白VI(PRX VI)和BMI1多梳环指癌基因(BMI-1))的自身抗体水平。我们评估了513名参与者的血清自身抗体：388名ESCC患者和125名正常对照。验证队列包括371名参与者：237名ESCC患者和134名正常对照。检测和验证队列中至少1种抗原自身抗体的敏感性/特异性分别为57%(95%可信区间：52-62%)/95%(95%可信区间：-98%)和51%(95%可信区间：45-57%)/96%(95%可信区间：91-99%)。自身抗体检测可以区分早期ESCC患者和正常对照(在测试队列中敏感性为45%(95%可信区间：32-59%)，特异性为95%(95%可信区间：89-98%)；在验证队列中为46%(95%可信区间：35-58%)和96%(95%可信区间：91-99%)。按年龄、性别、吸烟状况、肿瘤大小、肿瘤部位、肿瘤侵袭深度、组织学分级、淋巴结状况、TNM分期、早、晚期分组比较，两组间差异均无统计学意义。在优化的小组试验中测量对多种肿瘤相关抗原的自身抗体反应，以帮助区分早期ESCC患者和正常对照，可能有助于ESCC的早期检测。
Esophageal squamous cell carcinoma (ESCC) is one of the most frequent causes of cancer death worldwide and effective diagnosis is needed. We assessed the diagnostic potential of an autoantibody panel that may benefit early diagnosis. We analyzed data for patients with ESCC and normal controls in a test cohort and a validation cohort. Autoantibody levels were measured against a panel of six tumor-associated antigens (p53, NY-ESO-1, matrix metalloproteinase-7 (MMP-7), heat shock protein 70 (Hsp70), peroxiredoxin VI (Prx VI), and BMI1 polycomb ring finger oncogene (Bmi-1)) by enzyme-linked immunosorbent assay. We assessed serum autoantibodies in 513 participants: 388 with ESCC and 125 normal controls. The validation cohort comprised 371 participants: 237 with ESCC, and 134 normal controls. Autoantibodies to at least 1 of 6 antigens demonstrated a sensitivity/specificity of 57% (95% confidence interval (CI): 52–62%)/95% (95% CI: 89–98%) and 51% (95% CI: 45–57%)/96% (95% CI: 91–99%) in the test and validation cohorts, respectively. Measurement of the autoantibody panel could differentiate early-stage ESCC patients from normal controls (sensitivity 45% (95% CI: 32–59%) and specificity 95% (95% CI: 89–98%) in the test cohort; 46% (95% CI: 35–58%) and 96% (95% CI: 91–99%) in the validation cohort). In either cohort, no significant differences were seen when patients were subdivided by age, gender, smoking status, size of tumor, site of tumor, depth of tumor invasion, histological grade, lymph node status, TNM stage, or early-stage and late-stage groups. Measurement of an autoantibody response to multiple tumor-associated antigens in an optimized panel assay, to help discriminate early-stage ESCC patients from normal controls, may aid in early detection of ESCC.
登录
查看更多内容
影响因子：
6.4
作者：
CRAWFORD, LV;PIM, DC;BULBROOK, RD
通讯作者：
BULBROOK, RD
DOI：
10.1016/j.bbadis.2005.12.010
发表时间：
2006-04-01
影响因子：
6.2
作者：
Nesterova, M;Johnson, N;Cho-Chung, YS
通讯作者：
Cho-Chung, YS
影响因子：
2.6
作者：
Kosugi, S;Nishimaki, T;Hatakeyama, K
通讯作者：
Hatakeyama, K
影响因子：
3.4
作者：
Cheng, Y.;Xu, J.;Liu, L.
通讯作者：
Liu, L.
影响因子：
11.5
作者：
Desmetz, Caroline;Bascoul-Mollevi, Caroline;Solassol, Jerome
通讯作者：
Solassol, Jerome